查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587097

全球非鸦片类镇痛药市场评估：依药物类别、剂量类型、应用、给药途径、分布、地区、机会、预测（2017-2031）

Non-Opioid Pain Treatment Market Assessment, By Drug Class, By Medication Type, By Application, By Route of Administration, By Distribution, By Region Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 229 Pages | 商品交期: 3-5个工作天内

价格

全球非鸦片类止痛药市场规模预计将从 2023 年的 500.5 亿美元增至 2031 年的 916.8 亿美元，预计 2024-2031 年复合年增长率为 7.86%。对非阿片类镇痛药的市场需求是由于人们对阿片类药物危机以及与阿片类药物使用相关的风险（包括成瘾和过量）的认识不断提高而推动的，促使患者和医疗保健专业人员转向非阿片类药物等替代选择来缓解疼痛。

癌症疼痛、关节炎疼痛、背痛和心臟病等慢性疼痛疾病的盛行率不断增加，增加了市场对非鸦片类止痛药的需求。对非类固醇类抗发炎药物（NSAID）、非鸦片类止痛方法（如对乙酰氨基酚）和大麻素等新疗法的持续研究大大扩展了治疗选择。监管变化、政府和医疗保健组织正在对阿片类药物处方执行更严格的法规，并鼓励开发和使用非阿片类药物止痛方法。新的给药系统（例如透皮贴片、注射和植入装置）的开发正在提高非鸦片类药物治疗的有效性。 Semnur Pharmaceuticals 是一家治疗坐骨神经痛的非鸦片类止痛药开发商，已同意与 Denali Capital Acquisition Corp 合併。此次收购价值 25 亿美元，预计将于 2025 年第一季完成。合併完成后，Semnur 将扩展该公司旗舰注射皮质类固醇凝胶製剂地塞米松磷酸钠，旨在治疗中度至重度腰骶神经痛（俗称坐骨神经痛）。商业化之路。

本报告研究和分析了全球非鸦片类镇痛药市场，提供市场规模和预测、市场动态以及主要参与者的状况。

目录

第一章专案范围与定义

第二章研究方法

第 3 章执行摘要

第四章全球非鸦片类止痛药市场展望（2017-2031）

  • 市场规模分析与预测
    • 金额
  • 市占率分析与预测
    • 依药物类别
    • 依药物类型
    • 依用途
    • 依给药途径
    • 依分布
    • 按地区
    • 市占率分析：按公司划分（金额）（前 5 名公司及其他 - 2023 年）
  • 市场地图分析（2023 年）
    • 依药物类别
    • 依药物类型
    • 依用途
    • 依给药途径
    • 依分布
    • 按地区

第五章北美非鸦片类止痛药市场展望（2017-2031）

  • 市场规模分析与预测
    • 金额
  • 市占率分析与预测
    • 依药物类别
    • 依药物类型
    • 依用途
    • 依给药途径
    • 依分布
    • 分享：依国家/地区
  • 每个国家市场的评估
    • 美国非鸦片类止痛药市场前景（2017-2031）
    • 加拿大
    • 墨西哥

第六章欧洲非鸦片类止痛药市场前景（2017-2031）

  • 德国
  • 法国
  • 义大利
  • 英国
  • 俄罗斯
  • 荷兰
  • 西班牙
  • 波兰

第七章亚太非鸦片类止痛药市场前景（2017-2031）

  • 印度
  • 中国
  • 日本
  • 澳大利亚
  • 越南
  • 韩国
  • 印尼
  • 菲律宾

第8章南美洲非鸦片类止痛药市场前景（2017-2031）

  • 巴西
  • 阿根廷

第 9 章中东与非洲非鸦片类止痛药市场前景（2017-2031 年）

  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 南非
  • 以色列

第10章供需分析

第十一章进出口分析

第十二章价值链分析

第 13 章波特五力分析

第14章PESTLE分析

第十五章价格分析

第 16 章市场动态

  • 市场推动因素
  • 市场课题

第十七章市场趋势与发展

第 18 章监理架构与创新

  • 临床试验
  • 监理机关的核准

第十九章专利状况

第 20 章个案研究

第21章竞争态势

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 名的公司的 SWOT 分析
  • 前10名主要企业状况
    • Pfizer Inc.
    • Johnson & Johnson Services, Inc.
    • Teva Pharmaceuticals Industries Ltd.
    • Novartis AG.
    • Sun Pharmaceuticals Industries Ltd.
    • Fresenius Kabi AG
    • Dr.Reddy's Laboratories Ltd.
    • Cipla Inc.
    • Amgen Inc.
    • Sanofi S.A.

第22章策略建议

第23章关于我们公司，免责声明

Product Code: MX12220

Global non-opioids pain treatment market is projected to witness a CAGR of 7.86% during the forecast period 2024-2031, growing from USD 50.05 billion in 2023 to USD 91.68 billion in 2031. The market demands for non-opioid pain treatment pharmaceutical products is anticipated to thrive in the forecast period due to increased awareness of opioid crisis and risks associated with the use of opioids, including addiction and overdose, pushing both patients and medical workers to look for alternative options like non-opioids for treating pain.

An increase in the prevalence of chronic pain conditions such as cancer pain, arthritis pain, and lower back pain, heart disease has led to increases in an increased demand for non-opioid analgesics in the market. Ongoing research into new therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs), non-opioid pain relief methods such as acetaminophen, and cannabinoids, has significantly expanded the treatment options. Regulatory changes, governments, and healthcare organizations are implementing stricter regulations regarding the prescription of opioids and encouraging the development and use of non-opioid pain relief treatments. The development of new delivery systems, such as transdermal patches, injections, and implantable devices, increases the effectiveness of non-opioid treatments. Semnur Pharmaceuticals, a company developing a non-opioid treatment for sciatica, has agreed to merge with Denali Capital Acquisition Corp. The transaction is valued at USD 2.5 billion and is expected to close by the first quarter of 2025. Following the completion of the merger, Semnur aims to continue the path toward the potential commercialization of its leading drug candidate, Semdexa, which is an injectable corticosteroid gel formulation of dexamethasone sodium phosphate, designed to treat moderate to severe lumbosacral radicular pain, commonly known as sciatica.

Increasing Awareness of Risks Related to the Use of Opioids

Increasing awareness of risks related to the use of opioids has become an important issue in healthcare and has considerably improved the practice of pain. It is estimated that over 6.1 million people aged 12 or older have an opioid use disorder (OUD). This consciousness, which was pampered by the trend of opioids and led to unprecedented dependence levels, overdose, and death, emphasized the seriousness of the situation, causing a wide range of lighting and public health campaigns in the media. Personal stories and alarming statistics effectively illustrate the potential dangers of opioid medications and have contributed to a climate of concern. In response, healthcare organizations and patient advocacy groups have prioritized educational efforts aimed at both healthcare providers and patients. These initiatives highlight the risks of addiction and the importance of exploring non-opioid alternatives for pain relief. Regulatory bodies are implementing stricter guidelines on opioid prescriptions and are encouraging doctors to assess risks and consider safer treatment options. Increased awareness of risks related to the use of opioids will automatically reflect into increased demand for non-opioid drugs. In May 2023, the U.S. Food and Drug Administration approved Brixadi (buprenorphine), an extended-release injection for subcutaneous route to treat moderate to severe opioid use disorder (OUD). Brixadi is available in two formulations, a weekly injection that can be used in patients who have started treatment with a single dose of a transmucosal buprenorphine product. or who are already being treated with buprenorphine, and a monthly version for patients already being treated with buprenorphine.

Advancement in Pain Management Research

Recent advancements in pain treatment research are changing the way to manage chronic pain, driven by the need to find safer alternatives to opioids. Key developments include the advent of biologics and targeted therapies that focus on specific pain pathways, as well as neuromodulation techniques such as spinal cord stimulation, which modify nerve activity to provide relief. The growth of the non-opioid market is driven by the increasing prevalence of chronic pain which is affecting millions of individuals globally with conditions such as arthritis and lower back pain. Additionally, the aging population prevalence of the condition and lifestyle factors, poor diet, and obesity have been linked to a rise in conditions such as back pain, joint issues, and neuropathic pain. Neuropathic pain, which affects the nervous system, is exacerbated by conditions such as diabetic neuropathy and chemotherapy-induced peripheral neuropathy, so there is a huge demand for effective treatments. The industry's focus on developing suitable treatments for various types of chronic pain patients is supported by governing bodies. This will enable researchers and pharmaceutical companies to advance the treatment of chronic pain management. The rising awareness about chronic pain is driving the growth of the non-opioid analgesics market. For instance, in January 2024, researchers at the University of Texas at Austin identified a potential non-opioid treatment. A new approach to treating neuropathic pain is taking a key step forward. Neuropathic pain is among the most difficult types of pain to alleviate, and current treatments are often ineffective.

NSAIDs Segment to Dominate the Non-Opioid Pain Treatment Market

The NSAIDs segment is likely to dominate the non-opioid pain treatment as they most effectively alleviate pain and inflammation resulting from a variety of conditions. NSAIDs are commonly prescribed medications to treat mild to moderate-level pain and, therefore, they are the first-line prescribing option, due to their established efficacy and a favorable safety profile when given at recommended dosages. With several formulations available-from over the counter like ibuprofen or naproxen to prescription strength medications-NSAIDs represent versatility in pain management. The increasing use of NSAIDs is also promoted by growing awareness about the risks associated with opioid use as well as the campaigns and efforts for safer, nonaddictive alternatives for pain relief. This segment would likely expand further with more patients on the lookout for effective solutions with fewer side effects and overall dominance in the market for non-opioid pain treatment. For instance, in August 2023, Zydus Lifesciences was granted final approval from the Food and Drug Administration to manufacture and market generic indomethacin 50 mg suppositories. Indomethacin, a non-steroidal, anti-inflammatory therapy, is indicated for moderate to severe rheumatoid arthritis, including acute flares of chronic disease.

North America Dominates the Non-Opioid Pain Treatment Market

North America dominates the non-opioid pain treatment markets due to the prevalence of chronic pain, neuropathic pain, and postoperative surgical pain. Chronic pain is a condition that affects the daily life of many adults in the United States. Around 1 in 20 U.S. adults with chronic pain have clinically significant symptoms of anxiety and depression. Approximately 12 million Americans, 55.6% percentage of U.S. adults, report chronic pain and also have persistent anxiety or depression compared with 17.1% of adults with chronic pain who do not report symptoms of anxiety or depression. A 69.4% percentage of U.S. adults with coexisting chronic pain, depression, and anxiety disorders report that their health condition limits their ability to work. Meanwhile, 43.7% of this population reported difficulty running errands alone, and 55.7% said they had difficulty participating in social activities. In Oct 2023, Hyloris Pharmaceuticals, a Belgium-based pharmaceutical company, announced the U.S. Food and Drug Administration approved the New Drug Application for Maxigesic IV as a treatment for mild-to-moderate pain and adjunct therapy for moderate to severe pain. Partnering with AFT Pharmaceuticals, Hyloris developed Maxigesic IV as an alternative to opioid painkillers after surgical procedures.

Future Market Scenario (2024-2031F)

The non-opioid pain treatment market is poised to witness significant growth driven by ongoing concerns over opioid addiction and an increasing focus on comprehensive pain management solutions. Advancements in research and technology are likely to lead to the development of innovative non-opioid treatments, including targeted biologics, neuromodulation devices, and regenerative medicine techniques. Furthermore, the increasing prevalence of chronic pain, especially among the elderly, will continue to fuel the demand for effective pain management options. Regulatory support for non-opioid alternatives, along with increased awareness among healthcare providers and patients about the risks associated with opioid use, will further bolster the market dynamics. The integration of digital health solutions and telemedicine is expected to drive patient engagement and personalized care, improving access to non-opioid treatments. As these trends converge, the non-opioid pain treatment market is expected to expand significantly and become a key component of the future pain treatment landscape. Companies that will focus on developing advanced new formulations and alternative pain management solutions are likely to see growth in this market. Collaboration with regulators and healthcare providers is key to shaping a responsible future for the non-opioid pain treatment market.

Key Players Landscape and Outlook

The non-opioid pain management market is highly dynamic, with several leading players like Pfizer Inc., Johnson & Johnson Services, Inc., Teva Pharmaceuticals Industries Ltd., Novartis AG., Sun Pharmaceuticals Industries Ltd., Fresenius Kabi AG., Dr.Reddy's Laboratories Ltd ., Cipla Inc., Amgen Inc., Sanofi S.A. Corporation. Significant market activities have been reported in recent times including distribution agreements and acquisitions alongside several product launches. The market players are taking several initiatives and are actively involved in developmental moves to bring growth to this market.

On 30 Jan 2024, Vertex Pharmaceuticals' (VRTX.O), launched an experimental drug to decrease acute, post-surgical pain without the risk of addiction, a big milestone in the company's decades-long efforts to bring a non-opioid pain medicine to market. The company plans to file for U.S. approval by mid-2024 for the drug. The drug works by blocking pain signals at their origin before they reach the brain. If the drug gets approved, it could achieve an annual sale of more than USD 5 billion.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Non-Opioid Pain Treatment Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Drug Class
      • 4.2.1.1. NSAIDs
      • 4.2.1.2. Local anesthetics
      • 4.2.1.3. Anticonvulsants
      • 4.2.1.4. Antidepressants
    • 4.2.2. By Medication type
      • 4.2.2.1. Over-the-counter
      • 4.2.2.2. Prescription
    • 4.2.3. By Application
      • 4.2.3.1. Orthopaedic and Musculoskeletal Pain
      • 4.2.3.2. Postoperative Pain
      • 4.2.3.3. Cancer Pain
      • 4.2.3.4. Neuropathic Pain
      • 4.2.3.5. Other Pain
    • 4.2.4. By Route of Administration
      • 4.2.4.1. Oral
      • 4.2.4.2. Injectable
      • 4.2.4.3. Topical
      • 4.2.4.4. Others
    • 4.2.5. By Distribution
      • 4.2.5.1. Hospital Pharmacy
      • 4.2.5.2. Retail Pharmacy
      • 4.2.5.3. Others
    • 4.2.6. By Region
      • 4.2.6.1. North America
      • 4.2.6.2. Europe
      • 4.2.6.3. Asia-Pacific
      • 4.2.6.4. South America
      • 4.2.6.5. Middle East and Africa
    • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Drug class
    • 4.3.2. By Medication type
    • 4.3.3. By Application
    • 4.3.4. By Route of Administration
    • 4.3.5. By Distribution
    • 4.3.6. By Region

5. North Non-Opioid Pain Treatment Analgesics Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Drug Class
      • 5.2.1.1. NSAIDs
      • 5.2.1.2. Local anesthetics
      • 5.2.1.3. Anticonvulsants
      • 5.2.1.4. Antidepressants
    • 5.2.2. By Medication type
      • 5.2.2.1. Over-the-counter
      • 5.2.2.2. Prescription
    • 5.2.3. By Application
      • 5.2.3.1. Orthopaedic and Musculoskeletal Pain
      • 5.2.3.2. Postoperative Pain
      • 5.2.3.3. Cancer Pain
      • 5.2.3.4. Neuropathic Pain
      • 5.2.3.5. Other Pain
    • 5.2.4. By Route of Administration
      • 5.2.4.1. Oral
      • 5.2.4.2. Injectable
      • 5.2.4.3. Topical
      • 5.2.4.4. Others
    • 5.2.5. By Distribution
      • 5.2.5.1. Hospital Pharmacy
      • 5.2.5.2. Retail Pharmacy
      • 5.2.5.3. Others
    • 5.2.6. By Country Share
      • 5.2.6.1. United States
      • 5.2.6.2. Canada
      • 5.2.6.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Non-Opioids Pain Treatment Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Drug class
          • 5.3.1.2.1.1. NSAIDs
          • 5.3.1.2.1.2. Local Anesthetics
          • 5.3.1.2.1.3. Anticonvulsants
          • 5.3.1.2.1.4. Antidepressants
        • 5.3.1.2.2. By Medication type
          • 5.3.1.2.2.1. Over-the-counter
          • 5.3.1.2.2.2. Prescription
        • 5.3.1.2.3. By Application
          • 5.3.1.2.3.1. Orthopaedic and Musculoskeletal Pain
          • 5.3.1.2.3.2. Postoperative Pain
          • 5.3.1.2.3.3. Cancer Pain
          • 5.3.1.2.3.4. Neuropathic Pain
          • 5.3.1.2.3.5. Other Pain
        • 5.3.1.2.4. By Route of Administration
          • 5.3.1.2.4.1. Oral
          • 5.3.1.2.4.2. Injectable
          • 5.3.1.2.4.3. Topical
        • 5.3.1.2.5. By Distribution
          • 5.3.1.2.5.1. Hospitals Pharmacy
          • 5.3.1.2.5.2. Retail Pharmacy
          • 5.3.1.2.5.3. Others
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Non-Opioid Pain Treatment Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Non-Opioid Pain Treatment Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Non-Opioid Pain Treatment Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Non-Opioid Pain Treatment Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Import and Export Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

  • 18.1. Clinical Trials
  • 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Pfizer Inc.
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 21.3.2. Johnson & Johnson Services, Inc.
    • 21.3.3. Teva Pharmaceuticals Industries Ltd.
    • 21.3.4. Novartis AG.
    • 21.3.5. Sun Pharmaceuticals Industries Ltd.
    • 21.3.6. Fresenius Kabi AG
    • 21.3.7. Dr.Reddy's Laboratories Ltd.
    • 21.3.8. Cipla Inc.
    • 21.3.9. Amgen Inc.
    • 21.3.10. Sanofi S.A.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 3. Global Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 4. Global Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 5. Global Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 6. Global Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 7. Global Non-Opioid Pain Treatment Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 10. North America Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 11. North America Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 12. North America Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 13. North America Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 14. North America Non-Opioid Pain Treatment Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 17. United States Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 18. United States Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 19. United States Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 20. United States Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 21. Canada Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 23. Canada Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 24. Canada Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 25. Canada Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 26. Canada Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 27. Mexico Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 29. Mexico Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 30. Mexico Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 31. Mexico Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 32. Mexico Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 33. Europe Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 35. Europe Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 36. Europe Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 37. Europe Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 38. Europe Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 39. Europe Non-Opioid Pain Treatment Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 42. Germany Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 43. Germany Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 44. Germany Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 45. Germany Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 46. France Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 48. France Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 49. France Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 50. France Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 51. France Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 52. Italy Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 54. Italy Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 55. Italy Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 56. Italy Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 57. Italy Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 58. United Kingdom Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 60. United Kingdom Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 61. United Kingdom Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 62. United Kingdom Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 63. United Kingdom Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 64. Russia Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 66. Russia Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 67. Russia Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 68. Russia Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 69. Russia Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 70. Netherlands Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 72. Netherlands Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 73. Netherlands Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 74. Netherlands Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 75. Netherlands Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 76. Spain Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 78. Spain Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 79. Spain Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 80. Spain Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 81. Spain Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 82. Turkey Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 84. Turkey Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 85. Turkey Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 86. Turkey Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 87. Turkey Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 88. Poland Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 90. Poland Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 91. Poland Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 92. Poland Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 93. Poland Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 94. South America Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 96. South America Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 97. South America Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 98. South America Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 99. South America Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 100. South America Non-Opioid Pain Treatment Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 103. Brazil Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 104. Brazil Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 105. Brazil Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 106. Brazil Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 107. Argentina Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 109. Argentina Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 110. Argentina Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 111. Argentina Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 112. Argentina Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 113. Asia-Pacific Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 115. Asia-Pacific Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 116. Asia-Pacific Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 117. Asia-Pacific Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 118. Asia-Pacific Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 119. Asia-Pacific Non-Opioid Pain Treatment Market Share (%), By Country, 2017-2031F
  • Figure 120. India Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 122. India Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 123. India Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 124. India Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 125. India Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 126. China Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 128. China Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 129. China Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 130. China Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 131. China Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 132. Japan Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 134. Japan Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 135. Japan Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 136. Japan Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 137. Japan Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 138. Australia Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 140. Australia Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 141. Australia Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 142. Australia Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 143. Australia Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 144. Vietnam Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 146. Vietnam Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 147. Vietnam Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 148. Vietnam Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 149. Vietnam Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 150. South Korea Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 152. South Korea Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 153. South Korea Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 154. South Korea Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 155. South Korea Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 156. Indonesia Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 158. Indonesia Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 159. Indonesia Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 160. Indonesia Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 161. Indonesia Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 162. Philippines Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 164. Philippines Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 165. Philippines Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 166. Philippines Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 167. Philippines Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 168. Middle East & Africa Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 170. Middle East & Africa Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 171. Middle East & Africa Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 172. Middle East & Africa Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 173. Middle East & Africa Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 174. Middle East & Africa Non-Opioid Pain Treatment Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 177. Saudi Arabia Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 178. Saudi Arabia Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 179. Saudi Arabia Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 180. Saudi Arabia Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 181. UAE Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 183. UAE Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 184. UAE Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 185. UAE Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 186. UAE Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 187. South Africa Non-Opioid Pain Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Non-Opioid Pain Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 189. South Africa Non-Opioid Pain Treatment Market Share (%), By Medication Type, 2017-2031F
  • Figure 190. South Africa Non-Opioid Pain Treatment Market Share (%), By Application, 2017-2031F
  • Figure 191. South Africa Non-Opioid Pain Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 192. South Africa Non-Opioid Pain Treatment Market Share (%), By Distribution, 2017-2031F
  • Figure 193. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Medication Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Distribution Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023